Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 38 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March New on NCI’s Websites for March 2025 MOST POPULAR GreaterGood Partners with Organization of Hope to Deliver Toys and Necessities... January 5, 2022 EMA Recommends Granting a Conditional Marketing Authorisation for Pralsetinib September 28, 2021 Shortening Duration of Adjuvant Treatment from 6 to 3 Months Did... May 10, 2022 Teenage (…and young adult) kicks April 5, 2023 Load more HOT NEWS How To Respond When Your Parents Are Critical Of Your Parenting... Immunotherapy Combination That Targets TIGIT Receptor Shows Promise in Non-Small Cell... EMA Recommends Granting a Conditional Marketing Authorisation for Ciltacabtagene Autoleucel Charity ‘looks to the future with renewed optimism’
